Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)
By G. Rustin, I. Vergote, E. Eisenhauer, E. Pujade-Lauraine, M. Quinn, T. Thigpen, A. du Bois, G. Kristensen, A. Jakobsen, S. Sagae and 5 more. International Journal of Gynecologic Cancer, 2010
597 citations recorded by the source corpus.
Subfields: Obstetrics and Gynecology, Pathology and Forensic Medicine, Reproductive Medicine
View Paper: https://www.semanticscholar.org/paper/647623c0ab1a7fdffc92d0470895478b452f7f2d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Obstetrics and Gynecology
In Reproductive Medicine
Citations in the corpus
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, methodology): “According to GCIG criteria, progression or recurrence based on serum CA 125 levels is defined on the basis of a progressive serial elevation of serum CA 125 [48].”
- ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. (2019, background): “Can we develop accurate and sensitive circulating and tissue biomarkers both of response and relapse? The Gynecologic Cancer InterGroup (GCIG) has published a consensus document regarding the criteria that should be used in clinical trial protocols to define PFS after first-line therapy, as well as ”
- ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease (2019, background): “Can we develop accurate and sensitive circulating and tissue biomarkers both of response and relapse? The Gynecologic Cancer InterGroup (GCIG) has published a consensus document regarding the criteria that should be used in clinical trial protocols to define PFS after first-line therapy, as well as ”
- Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer (2018, background): “Bowel resection without ileostomy or colostomy 17 (14) 8 (7)”